Mother to baby cancer transmission during pregnancy is extremely rare, with only around 18 documented cases worldwide in over 150 years of medical literature. The placenta acts as a strong barrier that blocks cancer cells from reaching the baby in nearly every case, and the baby’s developing immune system handles the very few that do slip through. Inherited cancer risk through genes is a separate matter, where certain BRCA or hereditary syndromes can pass down without any direct cell transmission.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Maternal to fetal cancer transmission is one of the rarest events in oncology, far less common than the worry it causes among pregnant patients. The placenta and the baby’s immune system together make this an extraordinary occurrence, not a likely one, and the families I counsel through cancer during pregnancy are reassured by how settled the evidence is here.”

The pregnancy biology builds in two strong barriers against transmission.

• Physical barrier: The placenta works like a filter between mother and baby, blocking most cells, including cancer cells, from crossing the bloodstream divide in either direction.
• Immune defence: The baby’s developing immune system recognises foreign cells, including any maternal cancer cells that slip through, and typically destroys them before they take hold.
• Genetic mismatch: Cancer cells from the mother carry her genetic markers, which the baby’s immune system reads as foreign, making engraftment in the baby’s body very unlikely.
• Extraordinarily rare: Only around 18 confirmed cases of true cell transmission exist in published literature, working out to roughly one case per 500,000 pregnancies with cancer.

For patients whose pregnancy plan combines cancer treatment with surgery, robotic cancer surgery allows precise removal that minimises disruption to ongoing pregnancy care.

Two completely separate ideas often get confused. They work through totally different biology.

• Inherited cancer: Specific genes like BRCA1, BRCA2 or Lynch syndrome pass from parent to child at conception, raising lifetime cancer risk decades later, not at birth.
• Transmitted cancer: Actual cancer cells crossing from a mother’s body into the baby during pregnancy, which is the extremely rare event covered in this blog.
• Different timing: Inherited risk shows up years or decades after birth as cancer might or might not develop. Transmission shows up months after birth as direct disease.
• Genetic counselling: Anyone with a strong family cancer history benefits from genetic testing and counselling, which is the right path for inherited risk, not transmission worry.

For young women planning pregnancy after their own cancer treatment, our blog on pregnancy after cancer walks through timing and safety.

Dr. Sandeep Nayak has spent 24 years in surgical oncology, with DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco Surgery. He counsels pregnant patients facing a cancer diagnosis with calm, evidence based answers about transmission rarity, treatment options that protect both mother and baby and clear coordination with obstetric teams throughout.

That settled, evidence based reassurance is what carries patients through cancer in pregnancy without panic. Every case at MACS Clinic goes through a full tumour board, where the treatment plan is set together. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Hugging during chemotherapy is safe most of the time, and emotionally it matters a lot. What changes is the timing window after each cycle, when immunity dips, and the visitor’s own state of health on that day. There’s also a short body fluid precaution for the first 48 hours after an infusion, and beyond that, physical closeness through treatment is something patients genuinely need.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Cancer patients on chemo need closeness from family, not distance. The medical answer is simple. Healthy visitors can hug, kiss and stay close. What’s risky is bringing infection into a low immunity body, so the rule is one line. If you’re sick, stay away.”

A few things decide whether closeness is fine or worth pausing for that day.

• You’re healthy: No cold, no fever, no cough, nothing brewing? Then yes, hug freely. There’s no risk going from a healthy visitor to the patient through touch.
• Day of cycle: Immunity tends to drop hardest about 7 to 14 days after each chemo session. That’s the stretch where any extra caution matters more.
• Hand washing: A quick hand wash before any close contact does almost as much good as you can imagine. Everyday germs are the main thing you’re keeping away.
• Mask if unsure: Had a mild sniffle recently, or been around someone unwell? Wear a mask through the visit. Easy, cheap and worth the extra layer.

For patients whose plan combines chemo with surgery, robotic cancer surgery brings faster recovery so they return to family closeness sooner.

Day to day life needs only small tweaks, not a complete overhaul.

• 48 hour care: For about two days after an infusion, traces of chemo leave through urine and other body fluids. Use gloves when cleaning the toilet or washing soiled laundry.
• Sick visitors: If a visitor has a cold, flu, or even an unsettled stomach, ask them politely to come another day. Low immunity plus a small infection can mean a hospital admission.
• Shared meals: Eating together is fine. It’s actually good for the patient’s mood. Just keep regular hygiene with hand washing and clean utensils.
• Children visits: Healthy children can come over and hug freely. Skip the visit if the child has chickenpox, measles or anything contagious in the air.

For families wanting to understand how chemo cycles are scheduled and why timing shapes everything, our blog on chemo rounds for breast cancer walks through it.

Dr. Sandeep Nayak has spent 24 years in surgical oncology, with DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco Surgery. He briefs every family clearly on chemo timing, low immunity windows and what household precautions genuinely matter, so caregivers feel confident, not scared to be close.

That kind of direct, practical guidance turns the chemo experience from isolating into supported. Every case at MACS Clinic goes through a full tumour board, where the treatment plan is set together. Call +91 8104310753 to book your consultation.

Cancer drives weight loss through several things happening together. The tumour leaks inflammatory chemicals that ramp up metabolism and dampen appetite. The body burns more calories at rest. Add chemo, radiation or surgery side effects on top, and food intake drops too. Rarely just one cause. Usually four or five stacking up at once.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Cancer weight loss isn’t just about appetite or food. It’s a metabolic state where the body burns through itself to feed the cancer. Understanding that helps families stop blaming the patient for not eating enough, and helps the medical team plan support around treatment, not just diet.”

Several processes run at the same time. Each adds to the weight loss.

• Cytokine inflammation: The tumour pushes out proteins called TNF-alpha, IL-1, IL-6. These speed muscle breakdown. They suppress appetite too. So even patients who feel like eating struggle to use the food properly.
• Hypermetabolism: Cancer cells gulp huge amounts of glucose and nutrients to grow. Resting metabolism climbs. Reserves burn faster than normal eating can replace. The scale drops.
• Hormonal disruption: Insulin resistance kicks in. Catabolic hormones rise. Anabolic hormones fall. The balance tips toward tissue breakdown rather than tissue building.
• Treatment side effects: Chemo brings nausea, mouth sores, taste changes. Radiation to the gut or throat makes swallowing painful. Surgery limits food intake during recovery. Each compounds the underlying biology.

For patients whose cancer can be surgically removed, robotic cancer surgery brings precise tumour control with faster recovery, often slowing the metabolic chaos behind the weight loss.

Some cancers hit harder than others. Location and biology both play a role.

• Pancreatic cancer: The classic example. Around 80 percent of patients show weight loss at diagnosis. The pancreas controls digestive enzymes and blood sugar, so tumours here disrupt both at once.
• Stomach and oesophageal: Direct physical effect. Tumours block food, create early fullness, make swallowing tough. Patients eat less without quite realising it.
• Lung cancer: Strong inflammatory load. High cytokine levels drive systemic weight loss, even when the tumour itself is still small or early stage.
• Head and neck cancers: Pain with eating. Altered taste. Difficulty swallowing. Radiation side effects often compound the cancer’s direct effect on the appetite.

For patients dealing with digestive symptoms alongside weight loss, our blog on stomach cancer warning signs walks through the full symptom picture worth checking.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He treats cancer weight loss as part of the overall plan from the start, coordinating with oncology dietitians and supportive care teams so nutrition, medication and cancer treatment work together rather than in isolation.

Every case at MACS Clinic is reviewed by the multidisciplinary tumour board before treatment planning. Call +91 8104310753 to book your consultation.

PIPAC stands for Pressurised Intraperitoneal Aerosol Chemotherapy, a newer minimally invasive procedure that delivers chemotherapy as a pressurised mist directly into the abdominal cavity through small laparoscopic ports, repeated every six weeks alongside systemic chemo. HIPEC delivers heated liquid chemotherapy in a single major procedure after cytoreductive surgery. PIPAC is mainly used when full surgical removal isn’t possible, HIPEC when it is. Both target peritoneal cancer spread but in fundamentally different ways.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “PIPAC has changed what we can offer patients with peritoneal cancer spread that isn’t fully resectable. It’s not a replacement for HIPEC, it’s a different tool for a different group of patients, and the choice depends entirely on how extensive the spread is and what’s surgically achievable.”

PIPAC is a precise, minimally invasive chemotherapy delivery system. Here’s the breakdown.

• Aerosol delivery: Chemotherapy drugs are sprayed as a fine pressurised mist directly into the abdomen, reaching cancer cells across the peritoneal surface evenly.
• Pressure boost: The pressurised gas environment pushes the drug deeper into tumour tissue than liquid chemo achieves, improving local absorption significantly.
• Small incisions: Done laparoscopically through tiny ports, with no large cut, no organ removal, and patients usually discharged within one to two days.
• Repeated cycles: Given every six weeks alongside ongoing systemic chemotherapy, with three or more sessions typical depending on response.

So PIPAC is short, repeatable and minimally invasive. To understand the full peritoneal cancer treatment toolkit, the HIPEC treatment in Bangalore service page covers both PIPAC and HIPEC offered at MACS Clinic.

The two are often confused but work in fundamentally different ways. Here’s how they actually compare.

• Surgery scale: HIPEC needs full cytoreductive surgery first to remove visible tumour. PIPAC doesn’t, it’s chemotherapy delivery alone.
• Patient eligibility: HIPEC suits patients fit for major surgery with limited spread. PIPAC suits those whose disease is too spread for full surgery or who can’t tolerate major surgery.
• Intent of treatment: HIPEC aims to cure carefully selected patients. PIPAC is usually palliative or used to shrink disease enough for future surgery.
• Combined often: Some patients receive PIPAC first to reduce disease, then become candidates for HIPEC later, with the two working together rather than competing.

So the choice depends on the disease burden and surgical fitness, not patient preference. To understand outcomes after the more established HIPEC procedure, our blog on life expectancy after HIPEC surgery walks through what survival actually depends on for individual patients.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco Surgery to the care of patients with peritoneal cancer spread. He performs both HIPEC and PIPAC at MACS Clinic and KIMS Hospital Bangalore, choosing between them based on each patient’s disease burden and surgical fitness, not on what’s most commonly offered elsewhere.

That tailored selection between PIPAC, HIPEC or both is what gives peritoneal cancer patients the right tool for their specific situation. Every case at MACS Clinic goes through a full tumour board, where the treatment plan is set together. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute, Peritoneal Cancer Treatment. https://www.cancer.gov/
2. World Health Organisation, Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Chemotherapy uses drugs that attack all fast dividing cells in the body, including cancer cells but also healthy cells in hair follicles, the gut lining and bone marrow, which is why hair loss, nausea and low blood counts are common. Targeted therapy attacks only specific molecules or genetic mutations found in cancer cells, leaving most healthy cells alone, which means fewer broad side effects but its own distinct ones. Both are powerful, often used together, and the right choice depends entirely on the cancer’s biology.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The biggest misunderstanding patients carry into a treatment plan is thinking targeted therapy is simply a gentler chemo. It isn’t, it’s an entirely different approach that works only when your cancer has the specific molecular target the drug is designed for. That’s why the testing on the tumour matters as much as the drug choice itself.”

Chemotherapy is the foundational cancer drug treatment, and its mechanism is broad by design.

• Broad attack: Chemo drugs travel through the bloodstream and attack any cell dividing quickly, which includes cancer cells but also healthy ones.
• Healthy hit: Hair follicles, gut lining, bone marrow and nail beds are all hit too, which is where the visible side effects of chemo come from.
• Wide use: Works against most cancer types regardless of specific genetic profile, which makes it the backbone of treatment for many cancers.
• Cycle based: Given in scheduled cycles with rest periods between, allowing healthy cells time to recover before the next round.

So chemo’s strength is its breadth, but so is its main limitation. For patients whose treatment plan includes surgery, robotic cancer surgery works alongside chemo or targeted therapy in a complete treatment plan.

The two work on entirely different principles. Here’s how they actually compare.

• Test first: Targeted therapy needs molecular or genetic testing on the tumour first to confirm the specific target exists, which is why the biopsy matters.
• Different side effects: Targeted therapy usually avoids hair loss and nausea but can cause skin rashes, high blood pressure, fatigue and liver changes that need monitoring.
• Often combined: Many modern plans use both, with chemo killing existing cancer cells and targeted therapy blocking the pathways cancer needs to grow back.
• Not always option: If your tumour doesn’t have the molecular target, targeted therapy simply won’t work, which is why standard chemo remains essential for many cancers.

So the right choice depends entirely on what testing shows about the tumour. To understand what a chemotherapy course actually involves week by week, our blog on chemo rounds for breast cancer walks through cycles, decisions and what patients can expect.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco Surgery to the care of patients across every cancer type. He explains the targeted therapy and chemotherapy choice with the tumour’s actual test results in hand, so patients understand why a specific plan is recommended for them, not just told what to do.

That explanation built around your own tumour’s biology is what makes treatment decisions feel informed, not arbitrary. Every case at MACS Clinic goes through a full tumour board, where the treatment plan is set together. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute, Targeted Therapy for Cancer. https://www.cancer.gov/
2. World Health Organisation, Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer